Lung Cancer

Breakthrough therapy designation has been granted by the FDA to GSK5764227 for potential use in some patients with extensive-stage SCLC.

Higher corticosteroid peak dose may worse progression-free and overall survival in several tumor types including melanoma, non-small cell lung cancer, and others.

Fast track designation has been granted by the FDA to Deltacel with low-dose radiation for pretreated metastatic non–small cell lung cancer.

A behavioral intervention led by oncology nurses alleviated dyspnea in patients with advanced lung cancer, suggesting further research for long-term effects.

First-line amivantamab plus lazertinib has been approved by the FDA for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

Oncology nurses play a crucial role in educating patients about the significance of liquid biopsy in diagnosis and its use in evaluating resistance.

The KeyVibe-008 trial evaluating vibostolimab, pembrolizumab, and chemotherapy in extensive-stage small cell lung cancer has been discontinued.

Applying diversity, equity, and inclusion to cancer clinics can help oncology nurses and APPs make an impact on patient care and research.

Neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab, received approval from the FDA for select patients with resectable non–small cell lung cancer.

An expert explained how oncology nurses and APPs should stay informed on the latest genetic mutations that targeted therapies focus in on for non-small cell lung cancer.

Olanzapine improved control of nausea and vomiting from moderately emetogenic chemotherapy, which may suggest its use as a standard of care for antiemetic prophylaxis.

Atezolizumab was safe and effective when administered before and following chemoradiation in unresectable stage III non–small cell lung cancer.

Fast track designation has been awarded by the FDA to the next-generation precision radiopharmaceutical therapy ABD-147 to treat extensive-stage small cell lung cancer.

Crofelemer missed the diarrhea endpoint in a study assessing prophylaxis in adult patients with solid tumors receiving targeted therapy.

Based on in vitro studies, this tetravalent bispecific antibody may show binding affinity to PD1 and VEGF.

Oncology nurses can utilize risk assessment to predict patients at increased risk for cisplatin-induced acute kidney injury.

Follow-up with cholesterol control and audiological assessments is suggested for cisplatin-treated patients with cancer.

The failure to improve PFS and OS with tiragolumab plus atezolizumab and chemo in metastatic nonsquamous NSCLC indicates missing the primary end points of the SKYSCRAPER-06 trial.

Oncology nurses can provide patient and provider education about the benefits of stepped palliative care.

An sBLA was granted priority review from the FDA, which is seeking the approval of pembrolizumab plus chemotherapy for the frontline treatment of malignant pleural mesothelioma.

For oncology nurses, it is important to advocate for patients and families through ongoing assessments for caregiver burden, financial toxicity, and effective communication that lead to poor decision-making.

The biologics license application for subcutaneous amivantamab is seeking approval for the treatment of EGFR-positive non-small cell lung cancer.

The FDA granted accelerated approval to repotrectinib to treat adult and pediatric patients with NTRK gene fusion-positive solid tumors.

The priority review granted by the FDA to the supplemental new drug application for osimertinib is seeking approval for its treatment of stage III non-small cell lung cancer with EGFR mutations.

Adagrasib, compared with standard-of-care chemotherapy, significantly improved tumor responses and progression-free survival in patients with KRASG12C-mutated locally advanced or metastatic NSCLC.

Patients with advanced non-small cell lung cancer who received palliative care via telehealth had similar improvements in quality of life as those who received the care through in-person visits.

The survival benefit obtained from consolidation treatment with durvalumab after concurrent chemoradiation may change the standard of care for limited-stage small cell lung cancer.

Compared with placebo, osimertinib after definitive chemoradiotherapy improved progression-free survival in locally advanced, EGFR-mutated non–small cell lung cancer.

Patients with refractory EGFR-mutated, advanced non-small lung cancer had improved responses with low rates of adverse effects with subcutaneous amivantamab vs its intravenous formulation.

Frontline amivantamab plus lazertinib outperformed osimertinib regarding progression-free survival in patients with high-risk EGFR-mutant non-small cell lung cancer.